(Q40909946)
Statements
1 reference
A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis (English)
1 reference
Clemmesen B
1 reference
Ravn P
1 reference
Zegels B
1 reference
Taquet AN
1 reference
Christiansen C
1 reference
Reginster JY
1 reference
1 January 1997
1 reference
1 reference
7
1 reference
5
1 reference
488-495
1 reference
Identifiers
1 reference
1 reference